Our data suggest that downregulation of G9a promotes TPCs, leading to disease progression, metastasis, and worse clinical outcome, thus raising caution for the use of G9a inhibitors, particularly for lung cancer treatment. The gene discussed is EHMT2; the disease is lung carcinoma.